tiprankstipranks
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
Holding AVTX?
Track your performance easily

Avalo Therapeutics (AVTX) Financial Statements

889 Followers

Avalo Therapeutics Financial Overview

Avalo Therapeutics's market cap is currently ―. The company's EPS TTM is $-168.229; its P/E ratio is -0.06; Avalo Therapeutics is scheduled to report earnings on March 27, 2025, and the estimated EPS forecast is $-1.11. See an overview of income statement, balance sheet, and cash flow financials.
Sep 24Jun 24Mar 24Dec 23Sep 23
Income Statement-
Total Revenue$ 249.00K--$ 571.00K$ 236.00K
Gross Profit$ 963.00K$ -343.00K$ 80.00K$ 792.00K$ -11.00K
EBIT$ -12.86M$ 98.47M$ -5.23M$ -8.26M$ -3.67M
EBITDA$ -12.83M$ 98.50M$ -5.20M$ -8.21M$ -3.63M
Net Income Common Stockholders$ 23.04M$ 98.46M$ -121.29M$ -8.17M$ -5.23M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 81.86M$ 93.43M$ 110.18M$ 7.40M$ 10.20M
Total Assets$ 98.45M$ 108.31M$ 123.73M$ 20.99M$ 29.27M
Total Debt$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Net Debt$ -81.86M$ -93.43M$ -110.18M$ -7.40M$ -10.20M
Total Liabilities$ 75.72M$ 110.46M$ 236.27M$ 13.69M$ 14.57M
Stockholders Equity$ 21.08M$ -13.61M$ -112.54M$ 7.30M$ 14.70M
Cash Flow-
Free Cash Flow$ -11.50M$ -16.30M$ -6.20M$ -2.77M$ -6.84M
Operating Cash Flow$ -11.50M$ -16.30M$ -6.20M$ -2.77M$ -6.84M
Investing Cash Flow--$ 356.00K--
Financing Cash Flow-$ -472.00K$ 108.61M$ 1.00K$ 10.70M
Currency in USD

Avalo Therapeutics Earnings and Revenue History

Avalo Therapeutics Debt to Assets

Avalo Therapeutics Cash Flow

Avalo Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis